lexicon pharmaceuticals inc
(LXRX:Consolidated Issue Listed on Nasdaq Glbl Slct Mrkt)

Executive Profile*

Background*

Dr. Samuel L. Barker, Sam, Ph.D. is a Member of the Strategic Advisory Committee of Symphony Capital LLC. Dr. Barker has been the Chairman of the Board of Lexicon Genetics, Inc. since March 2005 and serves on the Board of Directors of UCB, United States. Dr. Barker has been a Director of Lexicon Genetics Inc. since March 2000. He has been an Independent Director of Cadence Pharmaceuticals, Inc. since 2008. Dr. Barker served at Bristol-Myers Squibb for over 35 years in ... research and development, manufacturing, business development, sales and marketing, and general management. After the merger of Bristol-Myers and Squibb in 1989, he assumed the position of Vice President of Asia-Pacific for the Pharmaceutical Group. Since 1991, he served as the President of Intercontinental at Bristol-Myers Squibb Company. From 1992 to retiring in May 1999, he served as the President of United States Pharmaceuticals Group. Dr. Barker was Co-Founder of Clearview Projects, and served as its President and Chief Executive Officer from 2003 to 2004. He served as the Chairman of Lexicon Pharmaceuticals, Inc. since March 21, 2005 and has been its Director since March 2000. He served as a Director of Atherogenics Inc., since July 2006. Dr. Barker is a Member of the Board of Trustees at the Cancer Institute of New Jersey. He holds a Ph.D. in Bionucleonics from the School of Pharmacy at Purdue University. Dr. Barker received a B.S. from Henderson State College and a graduate degree from the University of Arkansas.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
LXRX:US	$2.21 USD	+0.03

COMPETITOR COMPENSATION